Updated Jul 16, 2026
Apel Daniel Joseph has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $934K.

Daniel Joseph Apel is the Chief Financial Officer at Arrowhead Pharmaceuticals, Inc., a biotechnology company focused on developing medicines that treat intractable diseases by silencing genes. He has a background in finance and corporate management, contributing to the financial strategies and operations of the company.
| Role | Chief Financial Officer |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-24 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 8.7K | $71.92 | $628K |
| 2026-04-24 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 1.2K | $70.45 | $82K |
| 2026-04-24 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 3.2K | $70.11 | $225K |
Daniel Joseph Apel is the Chief Financial Officer at Arrowhead Pharmaceuticals, Inc., a biotechnology company focused on developing medicines that treat intractable diseases by silencing genes. He has a background in finance and corporate management, contributing to the financial strategies and operations of the company.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($934K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Apel Daniel Joseph profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.